Mivacurium
Mivacurium is a short-acting, non-depolarising neuromuscular blocking agent used during general anaesthesia to temporarily relax skeletal muscles and facilitate endotracheal intubation and surgical procedures. It works by competitively blocking acetylcholine receptors at the neuromuscular junction, preventing nerve signals from triggering muscle contraction. Mivacurium is supplied as an intravenous injection and is administered by trained anaesthesia professionals. Common effects include muscle weakness and temporary respiratory muscle paralysis, while histamine release may cause flushing, low blood pressure, or bronchospasm. Prolonged paralysis may occur in patients with reduced plasma cholinesterase activity, including those with certain inherited enzyme deficiencies. Administration requires continuous monitoring of neuromuscular function, breathing, and cardiovascular status, with assisted ventilation available until normal muscle function returns.
Mivacurium was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Mivacurium, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Mivacurium from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Mivacurium, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
